This is an aggregated industry headline. Read the full story at FiercePharma →
J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest products ever," CEO Joaquin Duato said on the company's first-quarter earnings conference call.
By FiercePharma
· Apr 17, 2026
· via FiercePharma
Image: FiercePharma
Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
MoneyFierceBiotech ↗
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…